男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影

AstraZeneca to build $200m center in China

Updated: 2011-10-12 09:56

By Ma Zhenhuan (China Daily)

  Comments() Print Mail Large Medium  Small 分享按鈕 0

AstraZeneca to build $200m center in China

AstraZeneca PLC workers load blister strips onto a packing line at a factory in Macclesfield, United Kingdom. The UK-based medical company will create 600 jobs by building a new factory in Taizhou, Jiangsu province. [Photo / Bloomberg]

SHANGHAI - AstraZeneca PLC, one of the world's leading pharmaceutical companies, said it would invest $200 million to launch a new manufacturing facility in China to meet growing demand, including in rural areas.

Construction work on the project, in the China Medical City in Taizhou of East China's Jiangsu province, is scheduled for completion by the end of 2013, creating approximately 600 jobs.

This will be London-based AstraZeneca's largest single investment in a manufacturing facility globally. The new plant will produce intravenous and oral solid products, the company said.

"The new facility will significantly enhance our capacity and allow us to meet the growing healthcare demand of the Chinese population, and help us expand into the 900 million (rural) people outside of the big cities and hospitals," Mark Mallon, president of AstraZeneca China, told China Daily in an exclusive interview on Monday.

"It will also allow us to free up some capacity at our existing manufacturing facility in Wuxi, Jiangsu, to bring on more new innovative products that will be launched over the next few years," he added.

The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010, according to market research agency IMS Health Inc, and it is expected to reach $102 billion by 2015.

Mallon said that he believes the Chinese government's focus on healthcare reform and investment in improving healthcare infrastructure and expanding insurance coverage will continue to drive the company's business growth and increase access to quality medicines over the longer term.

AstraZeneca will launch two new products, Faslodex, a treatment for breast cancer, and Onglyza, a new treatment for Type-2 Diabetes, in China this year.

Mallon also mentioned that the company is planning to launch Brilinta, an oral antiplatelet treatment for acute coronary syndrome, next year in China.

With an enhanced manufacturing capacity and the launch of more innovative new medicines, the company is planning to produce more affordable medicines for Chinese patients. It will adopt a multi-channel approach to sell its products to markets beyond big cities and hospitals.

Aside from the medical sales representatives who deal with individual physicians in big cities, the company has developed a team of about 100 customer service representatives who organize educational programs for small clinics and community health centers in China's rural areas.

It will also set up an inbound and outbound call center to reach out to healthcare professionals through phone calls, helping them learn more about AstraZeneca products, he said.

The company, which entered China in 1993, has invested about $500 million in the country, including an innovation center in Zhangjiang, Shanghai.

主站蜘蛛池模板: 常德市| 黔西| 崇州市| 禹城市| 惠州市| 鄂伦春自治旗| 来凤县| 日照市| 石渠县| 天台县| 宾川县| 探索| 台北县| 任丘市| 温宿县| 旬阳县| 天祝| 克拉玛依市| 锡林郭勒盟| 天津市| 杭锦后旗| 扎鲁特旗| 日土县| 金寨县| 洪雅县| 海城市| 湘乡市| 岳池县| 张家口市| 常州市| 松原市| 海淀区| 长岛县| 鱼台县| 磐安县| 安国市| 上杭县| 霸州市| 安平县| 郸城县| 上高县| 旬邑县| 砚山县| 慈溪市| 汉寿县| 平罗县| 巴东县| 紫金县| 雷波县| 安福县| 保靖县| 潜江市| 七台河市| 阿拉尔市| 黔江区| 镶黄旗| 古交市| 普安县| 潍坊市| 南和县| 义马市| 阿坝县| 山西省| 伊宁县| 凌云县| 江永县| 上饶县| 秦安县| 察雅县| 宜良县| 南澳县| 会同县| 商洛市| 太康县| 龙陵县| 马鞍山市| 铅山县| 平陆县| 化隆| 吴桥县| 特克斯县| 沁源县|